Magenta Therapeutics Cofounder David Scadden Honored at the American Society of Hematology Annual Meeting, as Scientific Founders Present New Stem Cell Biology Data


Magenta Therapeutics, a biotechnology company harnessing the power of stem cell science to revolutionize hematopoietic stem cell transplantation for patients with blood-based and immunologic diseases, today announced four oral presentations from scientific founders of the company at the upcoming American Society of Hematology Annual Meeting (ASH) in San Diego, California.

The presentations describe novel strategies for conditioning patients for transplantation using antibodies rather than highly toxic chemotherapies and irradiation, and methods for improving the process of harvesting stem cells for transplant based on work from their laboratories.

David Scadden, M.D., professor of medicine, and chair and professor of the department of Stem Cell and Regenerative Biology at Massachusetts General Hospital and Harvard University has been awarded the prestigious E. Donnall Thomas Lectureship and Prize, named in honor of the Nobel Laureate who pioneered bone marrow transplantation.

Dr. Scadden is chief scientific advisor, chair of the scientific advisory board and cofounder of Magenta and will give the E. Donnall Thomas Lecture entitled: “Bone Marrow: Structure and Function of the Blood Foundry” on Monday, December 5.

“We are delighted that the American Society of Hematology is honoring David with this prize. David’s contribution to the field of bone marrow transplant during his career has made a durable impact to our scientific and clinical understanding of hematopoietic stem cells, and he has influenced many of our careers along this journey,” said Jason Gardner, D.Phil., chief executive officer, president and cofounder of Magenta.

Additional abstracts from Magenta scientific founders selected for oral presentations include:

Abstract #368: Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell presented by Jonathan Hoggatt, Ph.D., assistant professor at Massachusetts General Hospital and Harvard Medical School, and Magenta scientific founder, on Sunday, December 4.

Abstract #493: Completely Non-Myeloablative/Non-Lymphoablative Conditioning for BMT/HSCT Using Anti-ckit Immunotoxins presented by Agnieszka Czechowicz, M.D., Ph.D., Clinical Fellow at the Dana Farber Cancer Institute, working in Magenta cofounder Dr. Derrick Rossi’s laboratory at Boston’s Children’s Hospital and Harvard Medical School in collaboration with Rahul Palchaudhuri, Ph.D. in Dr. David Scadden’s laboratory, on Sunday, December 4.

Abstract #659: Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice presented by Darja Karpova, Ph.D. from Magenta cofounder, Dr John DiPersio’s laboratory at Washington University on Monday, December 5.

“Magenta is honored to have assembled a distinguished group of scientific founders, including Drs. Hoggatt, Czechowicz and Palchaudhuri, each of whom are emerging as leaders in their field. The selection of these abstracts for oral presentation at such an important conference is a testament to the significance of their work and the promise of these approaches for innovating the practice of hematopoietic stem cell transplantation,” said Michael Cooke, Ph.D., chief scientific officer of Magenta Therapeutics.

About Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immunologic and blood-based diseases. By creating a platform focused specifically on hematopoietic stem cell transplantation, Magenta Therapeutics is pioneering a holistic, modular approach to design personalized therapies that refresh and reset the immune system and create synergistic patient benefit throughout the continuum of care. Founded by internationally recognized leaders in hematopoietic stem cell transplant, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Ventures and is headquartered in Cambridge, Mass. For more information, please visit

View source version on